Firm also acquired exclusive rights to a Phase II candidate.
BN ImmunoTherapeutics and the NCI are joining forces to develop new immunotherapies for prostate cancer. According to the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property (IP) that results from this collaboration.
Through this partnership and a license deal with the United States Public Health Service, BN ImmunoTherapeutics has also obtained rights to IP covering a Phase II vaccine candidate.
Data from clinical studies of this vaccine are currently being evaluated, according to the company.
